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More  than  1  million  people  die  of  lung  cancer  each  year  (1). 
Although smoking is the major etiologic factor, most smokers will 
not develop lung cancer (2), indicating that additional cofactors are 
needed for lung carcinogenesis. Lung cancer is also a major cause 
of cancer deaths even among never-smokers (3).
Certain types of human papillomavirus (HPV) are firmly estab-
lished as human carcinogens. These HPV types cause essentially all 
human  cervical  cancers  (4,5)  and  are  strongly  implicated  in  the 
etiology of a substantial proportion of other anogenital cancers (6) 
and oropharyngeal cancers (7,8). HPV has been hypothesized to 
play a role in lung cancer pathogenesis, largely on the basis of more 
than 50 studies (9,10) in which HPV genomic DNA was detected 
in 0%–100% (median = 16.7%) of lung tumor tissues. However, 
these studies are not definitive because of power constraints, re-
stricted  study  populations,  use  of  nonspecific  and/or  insensitive 
laboratory approaches, and use of HPV detection techniques that 
are limited to regions of the viral genome that may be lost with viral 
integration into the cellular host DNA. Although geographic dif-
ferences in the prevalence of HPV could potentially explain some 
variability in study results, interlaboratory variability and inade-
quate sample collection and handling leading to contamination may 
also contribute to the variability in reported results (10). Therefore, 
the role of HPV in lung carcinogenesis remains unclear.
Part of the reason why HPV is hypothesized to be associated 
with lung carcinogenesis is because the respiratory tract is in close 
proximity  to  the  oropharynx,  where  HPV  is  known  to  cause  a 
substantial proportion of cancers (7,8). HPV has been detected in 
respiratory papillomas, which are sometimes found in the bronchi 
and  occasionally  progress  to  malignancy,  and  also  has  been 
detected in respiratory tumors, as noted above (9,10). In addition, 
HPV can transform bronchial cells in vitro (11).
Furthermore, cervical cancer survivors and immunosuppressed 
populations are at increased risk for lung cancer and established 
HPV-related  malignancies  (12–14).  Although  smoking  is  an 
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established cofactor for cervical squamous cell carcinoma, it is not 
associated with an increased risk of cervical adenocarcinoma (15). 
However, cervical adenocarcinoma survivors have approximately 
twofold  increased  risk  of  lung  cancer  (16).  In  addition,  HIV–
AIDS patients, who have an increased risk of HPV and HPV-
related  malignancies  (17),  also  have  an  increased  risk  of  lung 
cancer that has not been completely accounted for by increased 
smoking (13). These epidemiological data are consistent with a 
hypothesis that HPV contributes to respiratory carcinogenesis in 
a smoking-independent manner.
A difficulty with the hypothesis that HPV is a lung carcinogen 
is the fact that HPV is not generally transmitted as an aerosol, 
making transmission to the lung difficult (18). However, the exis-
tence  of  rare  recurrent  respiratory  papillomatosis  demonstrates 
that HPV can reach the respiratory tract. In addition, recurrent 
respiratory papillomatosis shows a second peak in young adults 
aged approximately 20 years (19) that is associated with oral sex 
and number of lifetime sex partners (20), consistent with sexual 
transmission. The oral cavity, in which HPV infections are estab-
lished largely through sexual transmission (21), may act as a reser-
voir  for  transmission  of  HPV  to  the  respiratory  tract,  possibly 
through aspiration or mucosal transfer. The probability of such 
transmission may be exceedingly low, however, considering the 
rarity of recurrent respiratory papillomatosis.
The goal of our study was to complete a more definitive evalu-
ation of HPV in lung cancer. We tested for the presence of HPV 
DNA with highly sensitive polymerase chain reaction (PCR) and 
took rigorous precautions against PCR contamination in tumor 
tissues from 450 lung cancer patients from the well-characterized 
population–based case–control study, Environment and Genetics 
in Lung Cancer Etiology (EAGLE).
Materials and Methods
Study Population
EAGLE is a large population-based case–control study with 2100 
lung cancer patients that was designed to investigate the genetic 
and environmental determinants of lung cancer and smoking per-
sistence (22). As previously described (22), individuals with newly 
diagnosed  lung  cancer  were  recruited  from  April  22,  2002,  to 
February 28, 2005, from 13 hospitals in the Lombardy region of 
Italy (see Notes). Each participant provided written informed con-
sent. The study was approved by the institutional review board of 
each  participating  hospital  and  university  in  Italy  and  by  the 
National Cancer Institute, Bethesda, MD. Lung cancer was diag-
nosed  by  standard  clinical  criteria  and  confirmed  by  pathology 
reports from surgery, biopsy, or cytology samples (approximately 
95% of patients) or through clinical history and imaging (approx-
imately 5% of patients) (22). Tumor histology was classified by the 
1999  World Health Organization Histological Typing of Lung 
and Pleural Tumors (23). The 13 Italian hospitals treat approxi-
mately 80% of all patients with newly diagnosed lung cancer in the 
area,  which  includes  more  than  1.3  million  people  aged  35–79 
years from five cities and surrounding towns and villages. EAGLE 
had  a  participation  rate  of  86.6%  among  lung  cancer  patients. 
Thus, participants in the EAGLE study should be broadly repre-
sentative of lung cancer patients in Western populations.
We  decided  to  test  450  adult  male  and  female  lung  cancer 
patients, including all 30 never-smokers and a random sample of 
420  smokers  who  had  an  adequate  number  of  unstained  tissue 
slides and at least one slide available that was stained with hema-
toxylin and eosin. These stained slides were reviewed by H. Song 
to establish the presence and estimate proportion of tumor tissue 
in the sample, but these slides were not necessarily adjacent to the 
tissue that was tested for HPV DNA. The samples were formalin 
fixed for 399 patients and ethanol fixed for 51 patients.
HPV DNA Testing
All 450 patients were tested for HPV16 and HPV18 DNA because 
these are the most common types found in cervical cancer (24) and 
account  for  the  overwhelming  majority  of  noncervical  HPV–
associated  cancers  (25).  Type-specific  PCR  for  HPV16  and 
HPV18 was conducted in a laboratory at the Ohio State University, 
as  described  below.  For  a  subset  of  100  patients  including  all 
never-smokers and a random selection of smokers, a second tissue 
specimen was sent to DDL Diagnostic Laboratory (Voorburg, the 
Netherlands) for broad-spectrum HPV typing.
Type-Specific PCR for HPV16 and HPV18.  All specimen receipt, 
processing,  and  pre-amplification  analysis  procedures  were   
performed in ultraviolet light–irradiated laminar flow hoods in a 
CONTEXT AND CAVEATS
Prior knowledge
Human papillomavirus (HPV) is associated with cervical and oro-
pharyngeal cancers. A role for HPV in lung cancer has been pro-
posed, although previous reports of HPV in lung tumor tissue have 
been inconclusive.
Study design
Paraffin-embedded tissue specimens from 450 lung cancer patients 
who were smokers or never-smokers enrolled in the Environment 
and Genetics in Lung Cancer Etiology study were evaluated for 
HPV DNA by real-time polymerase chain reaction to determine the 
HPV prevalence in tissues from lung cancer patients in a represen-
tative Western population.
Contribution
Two specimens were found to be HPV positive at low copy number 
but were negative on additional genotype-specific testing and on 
testing for a broad spectrum of HPV types. The study found no 
evidence to support an association between HPV and lung cancer.
Implications
HPV  is  not  associated  with  lung  carcinogenesis  in  lung  cancer 
patients from a representative Western population.
Limitations
Multiple tissue specimens were used from each patient for analysis 
and were not necessarily adjacent to or from the same paraffin 
block. Also, the possible contamination of specimens during col-
lection could not be determined. Because of geographic variances 
in the prevalence of HPV reported in lung tumors, further studies in 
non-Western populations should be completed.
From the Editors
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laboratory with positive-pressure ventilation. All equipment and 
reagents were specific to the pre-amplification analysis laboratory 
with strict one-way transport of specimens from this laboratory to 
a  physically  separate  postamplification  analysis  laboratory. 
Additional protocols to prevent specimen contamination included 
sample processing in small batches, change of gloves after DNA 
extraction  of  each  sample,  exclusive  use  of  barrier  pipette  tips, 
weekly cleaning of all laboratory surfaces and equipment with 70% 
ethanol, and soaking of all racks and PCR plate holders in 10% 
bleach for a minimum of 10 minutes between each experiment. 
Additionally, one negative control per seven experimental samples 
was included in each column of each 96-well PCR plate.
DNA was extracted from 450 formalin- or ethanol-fixed paraffin-
embedded  tissue  samples  by  means  of  paraffin  removal  with 
octane, proteinase K digestion, phenol–chloroform extraction, and 
ethanol precipitation. Briefly, after octane exposure, the sample 
was washed with 100% ethanol, resuspended in 200 µL of diges-
tion buffer (50 mM Tris–HCl at pH 8.5, 1 mM EDTA, and pro-
teinase K at 20 µg/mL), and incubated for 48 hours at 55°C. If 
tissue remained, 10 µL of proteinase K (400 µg/mL) was added, 
and digestion was continued for an additional 24–48 hours. DNA 
was extracted in phenol–chloroform by use of Qiagen MaXtract 
tubes (Qiagen, Germantown, MD) and ethanol precipitated in the 
presence of glycogen (0.02 mg/mL). Pellets were washed once in 
70% ethanol, dried at 37°C in a dry incubator, and resuspended in 
50 µL of diethylene pyrocarbonate-treated water. DNA quantity 
and  purity  (calculated  by  use  of  the  ratio  of  the  absorbance  at   
260 nm to that at 280 nm [260/280 ratio]) were measured with the 
Nanodrop  spectrophotometer  (Thermo  Fisher  Scientific,  Inc, 
Wilmington, DE).
An estimate of the number of cells analyzed in each PCR was 
made by custom TaqMan real-time PCR assays targeting a single-
copy human gene on chromosome 7, human endogenous retrovi-
rus 3 (ERV3) (26). In a pilot study of 19 specimens, DNA integrity 
was  evaluated  through  amplification  of  ERV3  sequences  with 
primers generating an amplicon of 58, 135, or 354 base pairs (bp) 
in  size  (Supplementary  Table  1,  available  online).  Primer  and 
probe sequences for the 58-bp amplicon were as follows: forward 
primer, 5′-GATAATTTCACACTAACCGCC-3′; reverse primer, 
5′-AGATGCTCTGACTTGATGGT-3′; and the probe sequence, 
5′-56-FAM-CTCTTCCCTCGAACCTGC-3BHQ1-3′  (where 
56-FAM is 5′6-carboxy-fluorescein and 3BHQ1 is 3-Black Hole 
Quencher-1). Primer and probe sequences for the 135-bp ampli-
con  were  as  follows:  forward  primer,  5′-CATGGGAAGCAAG
GGAACTA-3′;  reverse  primer,  5′-CCCAGCGAGCAATACAG
AATTT-3′; and probe, 5′-56-FAM-TCTTCCCTCGAACCTG
CACCATCAAGTCA-3BHQ1-3′.  Primer  and  probe  sequences 
for  the  354-bp  amplicon  were  as  follows:  forward  primer, 
5′-CATGGGAAGCAAGGGAACTAATG-3′;  reverse  primer, 
5′-GCCCACAGATCCAGTAGAGG-3; and probe were the same 
as for the 135-bp amplicon above. Reaction conditions were as 
previously published (26). Briefly, purified genomic DNA (2 µL) 
from lung cancer specimens was analyzed. A standard curve was 
generated in duplicate from a fivefold dilution series (from 150 000 
to 1.92 cells) of a diploid human cell line, CCD-18LU (catalog 
number CCL-205, ATCC [American Type Culture Collection], 
Manassas, VA). Results were reported as the number of human 
diploid genome equivalents of purified genomic DNA from tumor 
samples that were evaluated for HPV16 and HPV18 DNA by real-
time PCR. All samples were tested once, and positive samples were 
retested  in  duplicate.  Although  DNA  was  degraded  because  of 
fixation, the mean yield was 54.5 ng/mL. This subset analysis indi-
cated that DNA integrity was sufficient to support amplification of 
targets with amplicon size between approximately 58 and 135 bp. 
The 58-bp ERV3 fragment was amplified for the 431 remaining 
specimens. DNA specimens with at least 100 evaluable cell equiva-
lents and a 260/280 ratio between 1.5 and 2.2 (27) were considered 
to have adequate DNA quantity and quality for further analysis.
Type-specific  TaqMan  real-time  PCR  targeted  to  the   
oncogenic E6 region of the genome for HPV16 (amplicon size = 
201 bp) and the E7 region of the genome for HPV18 (amplicon 
size = 137 bp) were performed in a 96-well plate format as previously 
described (28). To account for DNA degradation in formalin-fixed 
and paraffin-embedded tissues, all samples were also evaluated by 
means of a TaqMan real-time PCR assay designed to amplify an 
81-bp  amplicon  in  the  E6  region  of  the  genome  for  HPV16. 
Primers  and  probes  were  manufactured  at  IDT  Technologies 
(Coralville,  IA)  and  sequences  were:  forward,  5′-GAGAAC
TGCAATGTTTCAGGACC-3′; reverse, 5′-TGTATAGTTGT
TTGCAGCTCTGTGC-3′; and probe, 5′-56-FAMCAGGAGC
GACCCAGAAAGTTACCACAGTT-3BHQ1-3′. Standard curves 
were generated in duplicate by use of a fivefold dilution series from 
2.5  ×  10
6  copies  of  plasmid  vector  containing  full-length  viral 
genome  (pGEM  HPV16)  in  a  background  of  human  placental 
DNA  (5  ng/µL).  Reactions  that  were  performed  in  an  Applied 
Biosystems  7300  PCR  system  contained  2X  TaqMan  universal 
PCR master mix (Applied Biosystems, Foster City, CA), 0.1 µmol 
of probe, 0.2 µmol of each primer, and 2 µL of purified tumor 
DNA. Amplification conditions included a 12-minute incubation 
at  95°C,  followed  by  50  cycles  of  15  seconds  at  95°C  and   
60 seconds at 60°C. The cycle threshold (CT) of unknown samples 
was determined from an equation derived from a linear regression 
through the log CT of the standard curve according to the manu-
facturer’s recommendations. For positive samples, HPV viral load 
was normalized to ERV3 copy number by real-time PCR, as a 
measure of viral copy number per cell analyzed. Samples with any 
detectable  HPV16  or  HPV18  DNA  were  tested  in  duplicate,   
with a mean viral load of greater than one viral copy per sample 
classified as real-time PCR positive. A mean viral load of greater 
than or equal to one viral copy per cell was considered indicative 
of a clonal viral–tumor relationship.
Broad-Spectrum  HPV  Typing.  Specimens  from  all  30  never-
smokers and 70 randomly sampled current and former smokers 
were  selected  to  test  for  broad-spectrum  HPV  typing  at  DDL 
Diagnostic Laboratory. HPV typing used PCR with short PCR 
fragment (SPF10) primers, which targets the HPV L1 gene, and a 
mixture of conservative probes that recognize at least 54 mucosal 
HPV genotypes. We used the DNA enzyme immunoassay (DEIA) 
to determine HPV DNA positivity by detecting amplimers, syn-
thesized by biotinylated PCR primers, through hybridization to a 
mixture  of  HPV-specific  probes,  as  described  previously  (29). 
Stringent PCR contamination precautions that were similar to the 
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Ohio  State  University  were  taken.  All  pre-amplification  proce-
dures were performed in ultraviolet light–irradiated laminar flow 
hoods that were separate from a postamplification analysis labora-
tory. During DNA isolation, PCR amplification, and post-PCR 
analyses, specific negative (water blank) and positive (HPV DNA 
extracted from the HPV18-positive HeLa cell line) controls were 
included. We monitored potential contamination of samples with 
negative controls and the sensitivity of the procedure with low-
concentration positive controls. All reagents had been prepared in 
a separate reagent laboratory and subjected to strict quality control 
to confirm efficacy and the absence of contaminants.
DNA amplification by PCR with SPF10 primers was followed 
by  a  reverse  hybridization  line-probe  assay  (LiPA25,  version  1; 
Labo Bio-Medical Products, Rijswijk, the Netherlands) for geno-
typing of 25 HPV types in SPF10- and DEIA-positive samples. 
These  primers  produce  very  short  PCR  fragments  of  approxi-
mately 65 bp, making them ideal for amplification in formalin-
fixed specimens (29–31). Eight specimens did not appear to have 
tumors  in  the  tissue  specimen  received  for  testing.  DNA  was 
extracted for 92 specimens (from 65 ever-smokers and 27 never-
smokers) with identifiable tumor in the tissue specimen. For each 
specimen, half of the tissue section was removed from the slide 
with a swab after confirming the presence of tumor cells in that 
part of the section. This part of the tissue was transferred to a 
microtube (Sarstedt, Etten-Leur, the Netherlands) and digested 
with proteinase K buffer (45 mM Tris–HCl at pH 8, 0.9 mM 
EDTA,  0.45%  Tween  20,  and  proteinase  K  at  1  mg/mL). 
Proteinase K solution (100 µL) was added to each microtube and 
incubated  for  16–24  hours  at  56°C.  Proteinase  K  solution  was 
inactivated  by  incubating  the  tubes  at  95°C  for  10  minutes. 
Resulting DNA preparations were stored at 220°C. During this 
process, negative and positive DNA isolation controls were in-
cluded. In these samples, DNA quality and quantity were adequate 
as measured by real-time PCR for the human b-actin gene in the 
same DNA specimens as used for the SPF10 PCR. For one patient 
(a current smoker) where additional investigation was warranted 
due to weak HPV16 positivity in the sample tested at the Ohio 
State  University,  type-specific  PCR  for  HPV16  was  performed 
with a 92-bp amplicon as previously described (32).
Statistical Analysis
Our goal in determining sample size was to be able to rule out a 
true  HPV  prevalence  greater  than  1.0%.  Using  cii  in  Stata 
(StataCorp LP, College Station, TX), we determined that zero 
HPV positives among 450 lung cancer patients would generate a 
one-sided 97.5% confidence interval (CI) of 0% to 0.82% and that 
one  observed  HPV-positive  patient  among  450  lung  cancer 
patients would provide a two-sided 95% confidence interval of 
0.0056% to 1.2%; zero positives among 400 lung cancer patients 
would provide a one-sided 97.5% confidence interval of 0% to 
0.92%, and one observed HPV-positive patient would provide a 
two-sided  95%  confidence  interval  of  0.0063%  to  1.4%.  The 
chance of finding at least one positive when the true prevalence is 
1.0% or more was 98.9% with a sample size of 450 patients; thus, 
finding no positives with a sensitive assay rules out even a low 
prevalence of infection with high confidence.
In addition to the sample size calculations described above, we 
used the cii command in Stata (StataCorp LP), version 9.0, to 
estimate  HPV  prevalence  and  corresponding  confidence 
intervals.
Results
Among the 450 lung cancer patients, 246 (54.7%) had adenocarci-
noma and 137 (30.4%) had squamous cell carcinoma (Table 1). 
Most  patients  had  a  history  of  tobacco  smoking:  220  patients 
(48.9%) were current smokers, 198 patients (44.0%) were former 
smokers, and 30 patients (6.7%) were never-smokers. The median 
age at diagnosis of lung cancer was 67.6 years (range = 35.4–79.9 
years), and the median body mass index was 25.3 kg/m
2 (range = 
15.9–60.8 kg/m
2). Among smokers, the median duration of smoking 
was 45 years (range = 1–70 years), the median average smoking 
intensity was one pack per day (range = 0–3 packs per day), the 
median pack-years was 43.8 (range = 0.1–192 pack-years), and the 
median age at initiation of smoking was 16 years of age (range = 
6–45 years). Ninety-two patients (20.4%) were women. The ma-
jority of patients had less than a high school education (72.5% or 
319 patients), drank alcohol (84.3% or 365 patients), were married 
or cohabitating (82.2% or 356 patients), had abnormal respiratory 
Table 1. Characteristics of 450 lung cancer patients from the population-based case–control Environment and Genetics in Lung cancer 
Etiology study, including histology, smoking status, and human papillomavirus (HPV) status
Lung cancer histology
Smoking status, No. (%)
HPV DNA status by PCR* testing,  
No. (% HPV positive)
Never Former Current Unknown
Type-specific  
HPV16 and HPV18†
Broad-spectrum   
HPV typing‡
Adenocarcinoma (n = 246) 25 (83.3) 103 (52.0) 117 (53.2) 1 (50.0) 221 (0.0) 63 (0.0)
Squamous cell (n = 137) 2 (6.7) 68 (34.3) 66 (30.0) 1 (50.0) 123 (0.0) 27 (0.0)
Large cell (n = 30) 1 (3.3) 10 (5.1) 19 (8.6) 0 (0.0) 24 (0.0) 0 (0.0)
Small cell (n = 13) 0 (0.0) 5 (2.5) 8 (3.6) 0 (0.0) 11 (0.0) 0 (0.0)
Other (n = 24)§ 2 (6.7) 12 (6.1) 10 (4.5) 0 (0.0) 20 (0.0) 2 (0.0)
*  PCR = polymerase chain reaction.
†  Results from 399 specimens with adequate DNA of 450 selected for testing.
‡  Results from 92 specimens with tumor present in the sample of 100 selected for testing.
§  Includes mixed type (adenosquamous, n = 10), synchronous (two different lung cancers, n = 6), non-small cells (n = 2), and other (including poorly differentiated, 
epithelial, neuroendocrine, mucoepidermoid, non-small cell, pleomorphic, sarcomatoid, n = 6).jnci.oxfordjournals.org    JNCI | Articles 505
function (51.7% or 186 patients), and had stage IIB disease or less 
(71.3% or 321 patients) (Table 2).
The  median  number  of  cells  evaluable  for  the  HPV16  and 
HPV18 PCR as measured by ERV3 real-time PCR was 3680 cells 
(range = 1.9–399 750 cells). One specimen was negative for ERV3. 
The median 260/280 ratio was 1.63 (range = 1.23–1.94). Combining 
these  data,  399  (88.7%)  of  450  specimens  had  adequate  DNA 
quantity and quality for analysis (ie, 100 or more cell equivalents 
and a 260/280 ratio between 1.5 and 2.2). On review of the 450 
slides that were stained with hematoxylin and eosin, 412 specimens 
contained tumor cells. Of those tumor-positive specimens, 73.8% 
(n = 304 specimens) contained greater than 60% tumor. We in-
cluded all specimens with adequate DNA (n = 399 specimens) in 
the prevalence estimate.
Among  the  399  specimens  with  adequate  DNA,  one  female 
former smoker with adenocarcinoma was positive for HPV16 on 
initial testing. Given the very low viral load in this tumor (average 
=  0.4  per  1000  cell  equivalents  across  three  tests  of  the  same 
sample),  we  tested  another  tumor  tissue  specimen  from  this 
patient. We found no evidence of HPV16 or HPV18 DNA in this 
second specimen. The hematoxylin–eosin slide from this specimen 
consisted of greater than 80% cancer cells, indicating there was 
adequate  tumor  available  to  detect  any  HPV  DNA  if  it  were   
present. This patient was diagnosed with stage IB lung cancer at 
72 years of age and had smoked for 48 years at an average intensity 
of 0.75 packs per day (36 pack-years).
PCR analysis targeting an 81-bp amplicon in the HPV16 E6 
region confirmed the prior positive test (average of two viral copies 
per 1000 cell equivalents) in the first sample, and the second tumor 
tissue  specimen  from  this  patient  was  again  negative.  Another 
patient who was initially negative for HPV16 tested positive with 
this assay but at low copy number (131 per 1000 cell equivalents). 
This  second  patient  was  a  male  with  squamous  cell  carcinoma 
diagnosed at 64 years of age who had smoked for 43 years at an 
average intensity of one pack per day (43 pack-years). The hema-
toxylin–eosin slide from this patient also contained greater than 
80% cancer cells.
In the subset of 92 specimens tested with the broad-spectrum 
assay SPF10-DEIA-LiPA25 (including those from the two patients 
who tested positive with low viral load, as described above), no 
specimens were positive for HPV16 DNA or for any HPV type. 
DDL Diagnostic Laboratory conducted type-specific testing for 
HPV16 as a follow-up test for the male patient identified as being 
HPV positive by PCR analysis targeting an 81-bp amplicon in the 
HPV16 E6 region. The specimen tested negative for HPV DNA 
with this type-specific test. These results indicate that the preva-
lence of HPV DNA is 0.0% (Table 1) with an upper 97.5% confi-
dence  interval  of  0.92%  for  the  399  specimens  with  adequate 
DNA,  including  370  ever-smokers  (upper  97.5%  confidence 
bound = 0.99%) and 27 never-smokers (upper 97.5% confidence 
bound = 12.8%).
Discussion
In this study, which is to our knowledge the largest study of HPV 
in lung tumor tissue from a Western country, we found no evi-
dence that HPV is associated with lung carcinogenesis. Extensive 
laboratory efforts to avoid DNA contamination and state-of-the-
art, highly sensitive HPV DNA detection assays were performed. 
The two tumors that tested positive had a very low viral load of less 
than  one  copy  of  HPV16  per  cell,  despite  being  composed  of 
greater than 80% tumor cells. One of these patients tested nega-
tive in a separate tissue specimen, and the other was negative on 
additional type-specific HPV16 testing in a separate sample. None 
of the subset of 92 patients was positive for any other HPV type by 
the  very  sensitive  SPF10-DEIA-LiPA25  testing  method.  HPV-
related carcinogenesis at other anatomical sites indicates that HPV 
should be present in every tumor cell if it truly contributed to the 
development of that tumor (25). Thus, whereas low-level HPV 
positivity in one tissue sample and complete lack of HPV in a sep-
arate sample may be possible, such tumor heterogeneity is unlikely 
Table 2. Descriptive characteristics of 450 lung cancer patients 
from the population-based case–control Environment and 
Genetics in Lung cancer Etiology study*
Characteristic
No. of patients   
(% of total)
Age, y
  <60 93 (20.7)
  60–69 181 (40.2)
  ≥70 176 (39.1)
Sex
  Male 358 (79.6)
  Female 92 (20.4)
Area of Italy
  Brescia 72 (16.0)
  Milano 268 (59.6)
  Monza 54 (12.0)
  Pavia 22 (4.9)
  Varese 34 (7.6)
Education†
  None 27 (6.1)
  Elementary school 161 (36.6)
  Middle school 131 (29.8)
  High school (teaching training, job training,  
      college training)
105 (23.9)
  University degree (bachelor, master, PhD) 16 (3.6)
Alcohol consumption†
  No 68 (15.7)
  Yes 365 (84.3)
Marital status†
  Married or cohabitating 356 (82.2)
  Neither married nor cohabitating 77 (17.8)
Spirometry-based respiratory function†
  Normal 174 (48.3)
  Mild COPD 51 (14.2)
  Moderate COPD 68 (18.9)
  Severe and very severe COPD 17 (4.7)
  Potentially restrictive disease 50 (13.9)
Stage
  IA 84 (18.7)
  IB 126 (28.0)
  IIA 14 (3.1)
  IIB 97 (21.6)
  IIIA 58 (12.9)
  IIIB 43 (9.6)
  IV 28 (6.2)
*  COPD = chronic obstructive pulmonary disease.
†  Numbers do not sum to total because of missing values.506   Articles | JNCI  Vol. 103, Issue 6  |  March 16, 2011
to reflect a truly causal association. On the basis of these results, 
the prevalence of HPV in lung tumor tissue from this population 
was essentially 0%.
A limitation of this study was that the tissue specimens were not 
necessarily adjacent or from the same block, although as described 
above, lack of uniform HPV results throughout the tumor would 
suggest that HPV was not associated with tumorigenesis. Because 
tissue was collected for diverse purposes, it was not possible to 
address contamination in specimen collection. However, all labo-
ratory assays were performed under stringent precautions to avoid 
contamination. We also used viral load to assess whether detected 
HPV DNA was present at a meaningful level, as described above. 
Although DNA degradation may occur in paraffin-embedded tis-
sues, DNA quality was confirmed by satisfactory 260/280 ratio and 
real-time PCR for the human b–actin gene and/or ERV-3 in 399 
of the 450 specimens. These results indicate that the contamina-
tion precautions used during PCR analysis were largely sufficient 
to  avoid  contamination  and  that  the  DNA  from  the  paraffin-
embedded tissues was adequate for HPV DNA detection.
A particular strength of this study was that two independent 
laboratories extracted DNA (at the Ohio State University using 
phenol–chloroform extraction and at DDL Diagnostic Laboratories 
using crude extraction methods, as described in  “Materials and 
Methods”) from different tissue specimens from the same patient 
and conducted separate PCR assays for HPV DNA. All 450 spec-
imens were tested for the E6 and E7 oncogenes of HPV16 and 
HPV18, the two types most strongly associated with cancer out-
side  the  cervix  (25),  which  circumvented  concerns  about  false-
negative results because of loss of the L1 gene through integration. 
A  substantial  proportion  (92  specimens  from  450  lung  cancer 
patients)  was  tested  for  a  broad  range  of  HPV  types  with  the 
L1-based  SPF10-DEIA-LiPA25  system.  The  SPF10-DEIA-LiPA25 
system is the gold standard for HPV DNA testing in paraffin-
embedded  tissue  because  of  its  short  PCR  product  (31)  and 
ensured that specimens were tested for all carcinogenic and many 
noncarcinogenic HPV types.
Geographic  differences  in  the  prevalence  of  HPV  in  lung 
tumor tissue may be associated with variation in smoking habits, 
sexual behaviors, or other factors related to environmental expo-
sures, culture, topography, or genetics (10). Asian studies typically 
report  higher  PCR-based  HPV  prevalences  of  HPV  in  lung 
tumors than European studies, with a summary meta-estimate of 
11.6% (95% CI = 9.5% to 14.2%) for HPV16 and 8.8% (95%   
CI = 6.0% to 12.8%) for HPV18 in lung tumor tissues from Asia 
compared with 3.5% (95% CI = 2.3% to 5.3%) for HPV16 and 
3.6% (95% CI = 2.3% to 5.7%) for HPV18 in lung tumor tissues 
from  Europe  (10).  The  largest  PCR-based  Asian  studies  found 
HPV  DNA  in  42.0%  (n  =  92  specimens,  95%  CI  =  35.6%  to 
48.6%) of 219 paraffin-embedded lung tumor tissues (33,34) and 
44.1% (n = 138 specimens, 95% CI = 38.5% to 49.8%) of 313 
fresh-frozen lung tumor tissues (10,35). Similar to our study, the 
largest previous European PCR-based study from France found a 
very low prevalence of HPV DNA in 218 fresh-frozen lung tumor 
tissues (1.8% prevalence, 95% CI = 0.7% to 4.8%, n = 4 positive 
samples)  (10,36).  Part  of  this  geographic  discrepancy  may  be 
because  of  differences  in  smoking  habits.  For  example,  Asian 
women typically do not smoke. A study of lung cancer in Taiwan 
found that nonsmoking female lung cancer patients were more 
likely  to  have  HPV-positive  lung  tumor  tissue  than  male  lung 
cancer patients, who were more likely to smoke (37). Environmental 
tobacco exposure is unlikely to account entirely for the increased 
risk in never-smokers. Non–smoking-related factors must there-
fore contribute to lung cancer among never-smokers. Given the 
high upper confidence limit of our prevalence estimate in never-
smokers (12.8%), further study of HPV in lung tumor tissue from 
never-smokers may be warranted.
Nevertheless, the prevalence of HPV can vary markedly within 
the  same  country.  For  example,  the  PCR-based  prevalence  of 
HPV in lung tumor tissues from Japan ranges from 0.0% to 78.3% 
(10). Although we found essentially no HPV in lung tumor tissues 
from Italy, others have reported 12.8%–21.1% HPV DNA posi-
tivity in Italian lung cancer patients (10). Such disparities within 
the same geographic region emphasize the importance of taking 
precautions to avoid PCR contamination and prevent false-posi-
tive results (38) when using sensitive HPV DNA detection assays 
to avoid false-negative results. Our study used such precautions in 
two independent laboratories, verified DNA quality before HPV 
detection,  and  used  multiple  sensitive  methods  for  HPV  DNA 
detection. Although a few previous Asian and European studies 
have found 0% prevalence of HPV in lung tumor tissues, these 
studies included less than 100 patients. With nearly 400 patients 
evaluated, we had a sufficient sample size to detect any true preva-
lence of HPV greater than 1%. Our study was twice as large as the 
next largest study in Europe (n = 218 specimens).
In conclusion, using multiple state-of-the-art methods to eval-
uate the presence of HPV DNA in resected lung cancer tumors 
from a representative Western study population, we found no evi-
dence that HPV is associated with the development of lung cancer. 
Although we detected essentially no HPV in specimens from the 
EAGLE study, evaluation in a larger population of never-smokers, 
in which the attributable risk of non–smoking-related risk factors 
is necessarily higher, may be informative. Differences in smoking 
habits could potentially account for the higher prevalence of HPV 
DNA  detected  in  lung  tumor  tissue  from  Asian  countries.  For 
Western populations, however, this study found no data to support 
that HPV is associated with lung carcinogenesis.
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